results of the EORTC 18961 randomized phase III trial
The GM2 ganglioside is an antigen expressed in the majority of melanomas. The GM2-KLH/QS-21 vaccine induces high immunoglobulin M (IgM) and IgG antibody responses. The EORTC 18961 trial compared the efficacy of GM2-KLH/QS-21 vaccination versus observation.
Journal of Clinical Oncology, 2013, Vol 31, Issue 30, p. 3831-3837